DNMT3A and myelodysplastic syndrome: To further investigate the observed remodeling of the BM microenvironment in CHIP and MDS, we employed single cell transcriptomics on selected BM populations from a representative subset of the total cohort, comprising 3 Control, 3 CHIP (DNMT3A and/or TET2), and 4 MDS patients (SF3B1/SRSF2 and DNMT3A and/or TET2) (Fig. 2A, Supplementary Fig. 1A; more info in Supplementary Data 5).